662 related articles for article (PubMed ID: 22431433)
1. Long-term clinical outcome of rotational atherectomy followed by drug-eluting stent implantation in complex calcified coronary lesions.
Abdel-Wahab M; Baev R; Dieker P; Kassner G; Khattab AA; Toelg R; Sulimov D; Geist V; Richardt G
Catheter Cardiovasc Interv; 2013 Feb; 81(2):285-91. PubMed ID: 22431433
[TBL] [Abstract][Full Text] [Related]
2. High-speed rotational atherectomy before paclitaxel-eluting stent implantation in complex calcified coronary lesions: the randomized ROTAXUS (Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease) trial.
Abdel-Wahab M; Richardt G; Joachim Büttner H; Toelg R; Geist V; Meinertz T; Schofer J; King L; Neumann FJ; Khattab AA
JACC Cardiovasc Interv; 2013 Jan; 6(1):10-9. PubMed ID: 23266232
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
[TBL] [Abstract][Full Text] [Related]
4. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
[TBL] [Abstract][Full Text] [Related]
5. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
[TBL] [Abstract][Full Text] [Related]
6. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
Almalla M; Pross V; Marx N; Hoffmann R
Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
[TBL] [Abstract][Full Text] [Related]
8. Can intravascular ultrasound guidance modify the efficacy of drug-eluting stent over bare-metal stent in an aorto-ostial lesion?
Okabe T; Kawamura A; Maekawa Y; Anzai T; Iwanaga S; Yoshikawa T; Ogawa S
Cardiovasc Revasc Med; 2011; 12(2):105-10. PubMed ID: 21421189
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population.
Laynez A; Sardi G; Hauville C; Barbash IM; Pakala R; Torguson R; Xue Z; Satler LF; Pichard AD; Waksman R
Catheter Cardiovasc Interv; 2013 Apr; 81(5):759-65. PubMed ID: 22488756
[TBL] [Abstract][Full Text] [Related]
10. Comparison of abluminal biodegradable polymer biolimus-eluting stents and durable polymer everolimus-eluting stents in the treatment of coronary bifurcations.
Costopoulos C; Latib A; Naganuma T; Sticchi A; Ferrarello S; Regazzoli D; Chieffo A; Figini F; Carlino M; Montorfano M; Naim C; Kawaguchi M; Gerasimou A; Giannini F; Godino C; Colombo A
Catheter Cardiovasc Interv; 2014 May; 83(6):889-95. PubMed ID: 23804318
[TBL] [Abstract][Full Text] [Related]
11. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis.
Almalla M; Schröder J; Pross V; Marx N; Hoffmann R
Catheter Cardiovasc Interv; 2014 May; 83(6):881-7. PubMed ID: 23765557
[TBL] [Abstract][Full Text] [Related]
13. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
[TBL] [Abstract][Full Text] [Related]
14. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
[TBL] [Abstract][Full Text] [Related]
15. One-year outcome of patients with diabetes mellitus after percutaneous coronary intervention with three different revascularization strategies: results from the Diabetic Argentina Registry (DEAR).
Mieres J; Fernandez-Pereira C; Risau G; Solorzano L; Pauletto R; Rodriguez-Granillo AM; Rubilar B; Stella P; Rodriguez AE
Cardiovasc Revasc Med; 2012; 13(5):265-71. PubMed ID: 22796496
[TBL] [Abstract][Full Text] [Related]
16. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
17. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.
Kirtane AJ; Leon MB; Ball MW; Bajwa HS; Sketch MH; Coleman PS; Stoler RC; Papadakos S; Cutlip DE; Mauri L; Kandzari DE;
JACC Cardiovasc Interv; 2013 Apr; 6(4):325-33. PubMed ID: 23523453
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel- and sirolimus-eluting stents in older patients with diabetes mellitus: results of a real-life multicenter registry.
Buja P; Facchin M; Musumeci G; Frigo AC; Saia F; Menozzi A; Meliga E; Sardella G; Tamburino C; Tarantini G
Catheter Cardiovasc Interv; 2013 Jun; 81(7):1117-24. PubMed ID: 22936398
[TBL] [Abstract][Full Text] [Related]
19. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
[TBL] [Abstract][Full Text] [Related]
20. Impact of lesion calcification on clinical and angiographic outcome after sirolimus-eluting stent implantation in real-world patients.
Kawaguchi R; Tsurugaya H; Hoshizaki H; Toyama T; Oshima S; Taniguchi K
Cardiovasc Revasc Med; 2008; 9(1):2-8. PubMed ID: 18206630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
